Analysis of Clinical Characteristics of 54 Dead Pregnant Patients With Pulmonary Hypertension

Lishi Chen1, Shenpeng Zhou1, Jiaying Wang1

  • 1Department of Respiratory Medicine, Guangzhou Eighth People's Hospital Guangzhou Medical University Guangzhou China.

Pulmonary Circulation
|August 29, 2025
PubMed

To analyze the clinical characteristics and potential pregnancy outcomes of deceased pregnant women with pulmonary hypertension, we conducted a retrospective analysis of clinical data from 54 cases of pregnant women with pulmonary hypertension at The Third Affiliated Hospital of Guangzhou Medical University from May 2009 to February 2022. The results demonstrated that (1) Among 54 deceased pregnant patients with pulmonary hypertension (PH), 44 patients belonged to type 1, and 3, 2, and 5 patients belonged to type 2, type 4, and type 5, respectively. In type 1, 33 cases were secondary to congenital heart disease, with ventricular septal defect being common. (2) All 54 patients were diagnosed with PAH during pregnancy or postpartum. NYHA cardiac function grade II (10 cases), Ⅲ (18 cases), Ⅳ (26 cases), heart disease pregnancy risk levels were all Ⅳ. (3) Of the 54 patients, 7 patients had no data on the time of death, and most of them (37 patients) died within 1 week postpartum. (4) These 9 patients with mild PAH death during pregnancy had lower ejection fraction, higher rates of postpartum hemorrhage, left heart failure, systemic failure, arrhythmia, gestational diabetes, and infection than those with moderate or severe PAH death during pregnancy. As a consequence, deaths in pregnancies complicated with PH were mostly caused by PAH crisis, total heart failure, multiple organ failure, Eisenmenger syndrome and maternal perinatal mortality was high. The primary causes of mortality in pregnant women with mild PH include heart failure, respiratory failure, and arrhythmia etc. Patients experiencing complications such as postpartum hemorrhage, left ventricular dysfunction, multiorgan failure, arrhythmia, gestational diabetes mellitus, and infection may have a poorer prognosis.

Related Concept Videos

Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
284
Pulmonary Embolism I: Introduction01:29

Pulmonary Embolism I: Introduction

Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...
45
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
223
Mitral Valve Prolapse III: Nursing Management01:19

Mitral Valve Prolapse III: Nursing Management

The nursing management of Mitral Valve Prolapse, or MVP, centers around patient education, symptom monitoring, and lifestyle modifications.Patient Education on MVP Diagnosis and Heredity: Nurses should provide comprehensive education about MVP, a condition where the mitral valve does not close appropriately during heartbeats. This education often includes the condition's pathophysiology, symptoms, and potential complications, like arrhythmias or mitral regurgitation. Though not fully...
35
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
251
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
317